Skip to main content
Premium Trial:

Request an Annual Quote

Universal Sequencing Technology, Golden Gateway Partners Ink Australia Distribution Deal

NEW YORK – Universal Sequencing Technology (UST) said on Tuesday that Golden Gateway Partners will distribute its Transposase Enzyme Linked Long-read sequencing (TELL-Seq) kit in Australia.

Under the exclusive deal, Golden Gateway Partners will offer the Tell-Seq whole-genome sequencing library prep kit, which helps users generate long linked reads from short sequence reads. Financial and other terms of the deal were not disclosed.

"Golden Gateway Partners are experienced in assisting startup life science tools companies to grow commercially in the Asia Pacific region," UST said in a statement. "With a unique business model that enables a single distribution channel across the entire Asia Pacific region combined with UST's breakthrough technology, it created an ideal opportunity to develop a partnership."

UST, founded by next-generation sequencing industry veterans and based in Canton, Massachusetts, is offering the library prep kit while it builds a proprietary long-read sequencing platform.

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.